Statins and Selective Cyclooxygenase-2 Receptor Inhibitors in Blunt Chest Trauma
Status:
Unknown status
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
Background: Lung contusion affects 17%-25% of adult blunt trauma patients, and is the leading
cause of death from blunt thoracic injury. Statins are lipid-lowering drugs with recently
suggested anti-inflammatory and antioxidant properties. Cyclo-oxygenase-2 (COX-2) is a key
enzyme in the production of prostaglandins (PG), and evidence suggests that COX-2 plays an
important role in the pathogenesis of acute lung injury (ALI).
Aims: The current study aims at evaluating the beneficial effects of statins and COX-2
receptor inhibitors on ALI elicited by blunt trauma to the chest.
Methods: After approval by the institutional ethics and a scientific committee, and obtaining
informed consent , patients admitted to the emergency department (ED) due to blunt trauma
with a diagnosis of lung contusion will be enrolled in the study.The effects of statins and
COX 2 inhibitors on ALI will be assessed by recording clinical parameters and measuring
inflammatory mediators levels in the serum and in the bronchoalveolar space.
Expected results: The investigators expect to find that the proposed treatment will be
effective in reducing ALI burden. The investigators also suppose that using a combination of
those drugs will synergistically potentiate their effect on ALI.